Loratadine: A Potent, Nonsedating, and Long-Acting H1 Antagonist
- 1 June 1987
- journal article
- research article
- Published by SAGE Publications in American Journal of Rhinology
- Vol. 1 (2) , 95-99
- https://doi.org/10.2500/105065887781693321
Abstract
Loratadine, a nonclassical selective, peripheral H1-receptor antagonist has undergone extensive preclinical studies and clinical trials in over 6,000 patients. In the treatment of allergic rhinitis, loratadine has efficacy equivalent to clemastine, terfenadine, astemizole, and mequitazine. Its duration of action is 18–24 hours making once daily dosing practical. Loratadine is virtually devoid of sedating or other CNS effects.Keywords
This publication has 5 references indexed in Scilit:
- Studies on the central effects of the H1-antagonist, loratadineEuropean Journal of Clinical Pharmacology, 1987
- Antiallergic activity of loratadine, a non‐sedating antihistamineAllergy, 1986
- Selective displacement of [3H]mepyramine from peripheral vs. central nervous system receptors by loratadine, a non-sedating antihistamineEuropean Journal of Pharmacology, 1986
- Pharmacologic evaluation of loratadine (SCH 29851), chlorpheniramine and placeboEuropean Journal of Clinical Pharmacology, 1986
- Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamineInflammation Research, 1984